Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 13/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5152022 | 1.00 | ITGA4 (0.50) | ITGA4ITGB1MEN1RAB9AKMT2A | |
| SCHEMBL5149772 | 0.95 | ITGA4 (0.48) | ITGA4ITGB1MEN1RAB9AKMT2A | |
| SCHEMBL14558830 | 0.89 | ITGA4 (0.52) | ITGA4ITGB1ALDH1A1PYGL | |
| SCHEMBL14558358 | 0.87 | ITGA4 (0.55) | ITGA4ITGB1ALDH1A1PYGL | |
| SCHEMBL5152912 | 0.84 | ITGA4 (0.51) | ITGA4ITGB1RAB9AMAPTALDH1A1 | |
| SCHEMBL5155099 | 0.83 | ITGA4 (0.51) | ITGA4ITGB1ALDH1A1PYGL | |
| SCHEMBL5155094 | 0.82 | ITGA4 (0.44) | ITGA4ITGB1ALDH1A1 | |
| SCHEMBL14558349 | 0.81 | ITGA4 (0.57) | ITGA4ITGB1ALDH1A1PYGL | |
| SCHEMBL5149771 | 0.81 | ITGA4 (0.57) | ITGA4ITGB1ALDH1A1PYGL | |
| SCHEMBL14558345 | 0.80 | ITGA4 (0.61) | ITGA4ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ITGA4 4/4885ITGB1 8/4885MEN1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.